Vericel Corp director Robert L. Zerbe, M.D., filed a Form 144 notice on November 4, 2026, disclosing a proposed sale of 2,500 shares of Vericel common stock acquired through a stock option exercise.

Key Highlights

  • Seller: Robert L. Zerbe, M.D., identified in the filing as a Director of Vericel Corp.
  • Shares proposed for sale: 2,500 shares of common stock, with an aggregate market value of $113,501.89 according to the filing.
  • Source of shares: The filing states the securities were acquired via a stock option exercise from the issuer on November 4, 2026, with payment made in cash.
  • Shares outstanding: The filing lists 51,206,614 shares of common stock outstanding.
  • Exchange and broker: The proposed sale is to be executed on NASDAQ through Fidelity Brokerage Services LLC, 900 Salem Street, Smithfield, RI 02917.
  • Rule 10b5-1 plan: The filing indicates a plan adoption date of May 19, 2026.
  • Prior three-month sales: The filing reports nothing to report under securities sold during the past three months.

Zerbe's Proposed Sale Under Rule 144 at Vericel Corp

According to the Form 144 filing submitted on November 4, 2026, Robert L. Zerbe, M.D., a director of Vericel Corp (NASDAQ:VCEL), intends to sell 2,500 shares of the company's common stock. The filing lists the aggregate market value of those shares as $113,501.89. The proposed sale is to be conducted through Fidelity Brokerage Services LLC on the NASDAQ exchange, with an approximate sale date of November 4, 2026.

The filing discloses that the 2,500 shares were acquired on November 4, 2026, through a stock option exercise from the issuer, with full cash payment made on the same date. The filing also notes that the proposed sale is being made pursuant to a written trading plan adopted on May 19, 2026, under Rule 10b5-1 of the Exchange Act. The filing states that Zerbe reported no sales of Vericel securities during the three months preceding this notice.

Vericel Corp's issuer address is listed in the filing as 25 Blue Sky Drive, Burlington, Massachusetts 01803. The filing identifies the total shares of common stock outstanding as 51,206,614 at the time of the notice.

What Was Disclosed

Vericel Corp director Robert L. Zerbe, M.D., filed a Form 144 notice proposing the sale of 2,500 common shares with an aggregate market value of $113,501.89, acquired via a stock option exercise, under a Rule 10b5-1 plan adopted May 19, 2026.